Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T30926
(Former ID: TTDI02247)
|
|||||
Target Name |
GRB2 messenger RNA (GRB2 mRNA)
|
|||||
Synonyms |
SH2/SH3 adapter GRB2 (mRNA); Protein Ash (mRNA); Growth factor receptor-bound protein 2 (mRNA); Adapter protein GRB2 (mRNA); ASH (mRNA)
Click to Show/Hide
|
|||||
Gene Name |
GRB2
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 5 Target-related Diseases | + | ||||
1 | Acute myeloid leukaemia [ICD-11: 2A60] | |||||
2 | Malignant haematopoietic neoplasm [ICD-11: 2B33] | |||||
3 | Mature B-cell lymphoma [ICD-11: 2A85] | |||||
4 | Myelodysplastic syndrome [ICD-11: 2A37] | |||||
5 | Myeloproliferative neoplasm [ICD-11: 2A20] | |||||
Function |
Adapter protein that provides a critical link between cell surface growth factor receptors and the Ras signaling pathway.
Click to Show/Hide
|
|||||
BioChemical Class |
mRNA target
|
|||||
UniProt ID | ||||||
Sequence |
MEAIAKYDFKATADDELSFKRGDILKVLNEECDQNWYKAELNGKDGFIPKNYIEMKPHPW
FFGKIPRAKAEEMLSKQRHDGAFLIRESESAPGDFSLSVKFGNDVQHFKVLRDGAGKYFL WVVKFNSLNELVDYHRSTSVSRNQQIFLRDIEQVPQQPTYVQALFDFDPQEDGELGFRRG DFIHVMDNSDPNWWKGACHGQTGMFPRNYVTPVNRNV Click to Show/Hide
|
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
1 | BP-100-1-01 | Drug Info | Phase 2 | Myelodysplastic syndrome | [2] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Modulator | [+] 1 Modulator drugs | + | ||||
1 | BP-100-1-01 | Drug Info | [1], [3] |
Cell-based Target Expression Variations | Top | |||||
---|---|---|---|---|---|---|
Cell-based Target Expression Variations |
Target Profiles in Patients | Top | |||||
---|---|---|---|---|---|---|
Target Expression Profile (TEP) |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT01159028) Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS. U.S. National Institutes of Health. | |||||
REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032443) | |||||
REF 3 | Liposomal delivery of nucleic acid-based anticancer therapeutics: BP-100-1.01. Expert Opin Drug Deliv. 2015 Jul;12(7):1107-20. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.